Citations (55)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Yu-qing Hu & Jian-zhong Zhang. (2022) A Comparison for Type 2 Cytokines and Lesional Inflammatory Infiltrations in Bullous Pemphigoid and Atopic Dermatitis. Clinical, Cosmetic and Investigational Dermatology 15, pages 2313-2321.
Read now
Read now
Jue Liu, Tingkai Xiang, Wei Wang & Zhangyu Bu. (2022) Case Report: Omalizumab Successfully Treated Recalcitrant Bullous Pemphigoid in an Elderly Patient with Multiple Comorbidities. Clinical, Cosmetic and Investigational Dermatology 15, pages 1391-1396.
Read now
Read now
Pedro Miguel Garrido, Catarina Soares QueiróS, Ana Rita Travassos, João Borges-Costa & Paulo Filipe. (2022) Emerging treatments for bullous pemphigoid. Journal of Dermatological Treatment 33:2, pages 649-661.
Read now
Read now
Articles from other publishers (52)
Wu Han Toh, Hua-En Lee & Chun-Bing Chen. (2023) Targeting type 2 inflammation in bullous pemphigoid: current and emerging therapeutic approaches. Frontiers in Medicine 10.
Crossref
Crossref
Lingyu Hu, Ruiting Huang, Fuqiong Jiang, Shuqiong You & Qian Wu. (2023) Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: A preliminary study. Immunity, Inflammation and Disease 11:7.
Crossref
Crossref
Luyao Zhang, Zihua Chen, Lanting Wang & Xiaoqun Luo. (2023) Bullous pemphigoid: The role of type 2 inflammation in its pathogenesis and the prospect of targeted therapy. Frontiers in Immunology 14.
Crossref
Crossref
Anna Olewicz-Gawlik & Arleta Kowala-Piaskowska. (2023) Self-reactive IgE and anti-IgE therapy in autoimmune diseases. Frontiers in Pharmacology 14.
Crossref
Crossref
Vera Mahler. 2023. Berufsdermatologie. Berufsdermatologie
133
142
.
Giovanni Marco D’Agostino, Giulio Rizzetto, Andrea Marani, Samuele Marasca, Matteo Candelora, Daisy Gambini, Helena Gioacchini, Edoardo De Simoni, Andrea Maurizi, Anna Campanati & Annamaria Offidani. (2022) Bullous Pemphygoid and Novel Therapeutic Approaches. Biomedicines 10:11, pages 2844.
Crossref
Crossref
Faith A. P. Zeng & Dedee F. Murrell. (2022) Bullous pemphigoid—What do we know about the most recent therapies?. Frontiers in Medicine 9.
Crossref
Crossref
Bianca Opelka, Enno Schmidt & Stephanie Goletz. (2022) Type XVII collagen: Relevance of distinct epitopes, complement-independent effects, and association with neurological disorders in pemphigoid disorders. Frontiers in Immunology 13.
Crossref
Crossref
Connor Cole, Keshavamurthy Vinay, Luca Borradori & Kyle T. Amber. (2022) Insights Into the Pathogenesis of Bullous Pemphigoid: The Role of Complement-Independent Mechanisms. Frontiers in Immunology 13.
Crossref
Crossref
Kathleen D’Aguanno, Sofianne Gabrielli, Lydia Ouchene, Anastasiya Muntyanu, Moshe Ben-Shoshan, Xun Zhang, Lisa Iannattone & Elena Netchiporouk. (2022) Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of Efficacy and Safety. Journal of Cutaneous Medicine and Surgery 26:4, pages 404-413.
Crossref
Crossref
Khalaf Kridin, Christoph M. Hammers, Ralf J. Ludwig, Erez Onn, Yochai Schonmann, Abed Abu-Elhija, Dana Tzur Bitan, Enno Schmidt, Orly Weinstein & Arnon D. Cohen. (2022) The Association of Bullous Pemphigoid With Atopic Dermatitis and Allergic Rhinitis—A Population-Based Study. Dermatitis 33:4, pages 268-276.
Crossref
Crossref
Eva Martin, Isabell Mauer, Uwe Malzahn, Peter Ulrich Heuschmann, Matthias Goebeler & Sandrine Benoit. (2022) Komorbidität bei Patienten mit bullösem Pemphigoid in Deutschland: Ergebnisse einer Fall‐Kontroll‐Studie. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 20:6, pages 798-806.
Crossref
Crossref
Eva Martin, Isabell Mauer, Uwe Malzahn, Peter Ulrich Heuschmann, Matthias Goebeler & Sandrine Benoit. (2022) Comorbid diseases among bullous pemphigoid patients in Germany: new insights from a case‐control study. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 20:6, pages 798-805.
Crossref
Crossref
Sabrina Patzelt, Manuela Pigors, Heiko Steenbock, Leonard Diel, Katharina Boch, Lenche Chakievska, Sven Künzel, Hauke Busch, Anke Fähnrich, Jürgen Brinckmann & Enno Schmidt. (2022) Increased Fibrosis in a Mouse Model of Anti-Laminin 332 Mucous Membrane Pemphigoid Remains Unaltered by Inhibition of Aldehyde Dehydrogenase. Frontiers in Immunology 12.
Crossref
Crossref
Parisa Heydari, Mahshid Kharaziha, Jaleh Varshosaz & Shaghayegh Haghjooy Javanmard. (2021) Current knowledge of immunomodulation strategies for chronic skin wound repair. Journal of Biomedical Materials Research Part B: Applied Biomaterials 110:2, pages 265-288.
Crossref
Crossref
Lina Belmesk, Anastasiya Muntyanu, Emmanuelle Cantin, Zeinah AlHalees, Carolyn S. Jack, Michelle Le, Denis Sasseville, Lisa Iannattone, Moshe Ben-Shoshan, Ivan V. Litvinov & Elena Netchiporouk. (2021) Prominent Role of Type 2 Immunity in Skin Diseases: Beyond Atopic Dermatitis. Journal of Cutaneous Medicine and Surgery 26:1, pages 33-49.
Crossref
Crossref
Anuradha Bishnoi, Dipankar De, Sanjeev Handa & Rahul Mahajan. (2021) Biologics in autoimmune bullous diseases: Current scenario. Indian Journal of Dermatology, Venereology and Leprology 87, pages 611-620.
Crossref
Crossref
Xinyi Chen, Wenlin Zhao, Hongzhong Jin & Li Li. (2021) Risk Factors for Mucosal Involvement in Bullous Pemphigoid and the Possible Mechanism: A Review. Frontiers in Medicine 8.
Crossref
Crossref
Khalaf Kridin, Ralf J. Ludwig, Dana Tzur Bitan & Arnon D. Cohen. (2021) A History of Asthma Increases the Risk of Bullous Pemphigoid: Insights from a Large Population-Based Study. Dermatology 237:6, pages 921-928.
Crossref
Crossref
Erin E. Grinich & Eric L. Simpson. 2021. Comprehensive Dermatologic Drug Therapy. Comprehensive Dermatologic Drug Therapy
339
348.e4
.
D. Ferastraoaru, H. J. Bax, C. Bergmann, M. Capron, M. Castells, D. Dombrowicz, E. Fiebiger, H. J. Gould, K. Hartmann, U. Jappe, G. Jordakieva, D. H. Josephs, F. Levi-Schaffer, V. Mahler, A. Poli, D. Rosenstreich, F. Roth-Walter, M. Shamji, E. H. Steveling-Klein, M. C. Turner, E. Untersmayr, S. N. Karagiannis & E. Jensen-Jarolim. (2020) AllergoOncology: ultra-low IgE, a potential novel biomarker in cancer—a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI). Clinical and Translational Allergy 10:1.
Crossref
Crossref
Pedro Miguel Garrido, Maria Inês Alexandre, Ana Rita Travassos & Paulo Filipe. (2020)
Dipeptidyl‐peptidase
IV
inhibitor‐associated bullous pemphigoid efficiently treated with omalizumab
. Dermatologic Therapy 33:6.
Crossref
Crossref
Florentina Silvia Delli, Elena Sotiriou, Elizabeth Lazaridou, Zoe Apalla, Aimilios Lallas, Efstratios Vakirlis, Spyros Gerou, Konstantinos Bougioukas & Demetrios Ioannides. (2020)
Total
IgE
, eosinophils, and interleukins 16,
17A
, and 23 correlations in severe bullous pemphigoid and treatment implications
. Dermatologic Therapy 33:6.
Crossref
Crossref
Jessica L. Chandrasekhar, Kelly M. Cox & Loren D. Erickson. (2020) B Cell Responses in the Development of Mammalian Meat Allergy. Frontiers in Immunology 11.
Crossref
Crossref
A. Kamata, Y. Kurihara, T. Funakoshi, H. Takahashi, K. Kuroda, T. Hachiya, M. Amagai & J. Yamagami. (2019) Basement membrane zone IgE deposition is associated with bullous pemphigoid disease severity and treatment results. British Journal of Dermatology 182:5, pages 1221-1227.
Crossref
Crossref
Y. Ben Mordehai, H. Faibish, N. Astman, S. Greenberger, A. Barzilai & S. Baum. (2019) Characteristics of patients with bullous pemphigoid: comparison of classic bullous pemphigoid to non‐bullous pemphigoid. Journal of the European Academy of Dermatology and Venereology 34:1, pages 161-165.
Crossref
Crossref
Miao Yang, Haijing Wu, Ming Zhao, Christopher Chang & Qianjin Lu. (2019) The pathogenesis of bullous skin diseases. Journal of Translational Autoimmunity 2, pages 100014.
Crossref
Crossref
Nina van Beek & Enno Schmidt. 2019. Harper's Textbook of Pediatric Dermatology. Harper's Textbook of Pediatric Dermatology
868
897
.
Christian D. Sadik & Enno Schmidt. (2019) Resolution in bullous pemphigoid. Seminars in Immunopathology 41:6, pages 645-654.
Crossref
Crossref
Kelly N. Messingham, Tyler P. Crowe & Janet A. Fairley. (2019) The Intersection of IgE Autoantibodies and Eosinophilia in the Pathogenesis of Bullous Pemphigoid. Frontiers in Immunology 10.
Crossref
Crossref
Sandra Saschenbrecker, Ingolf Karl, Lars Komorowski, Christian Probst, Cornelia Dähnrich, Kai Fechner, Winfried Stöcker & Wolfgang Schlumberger. (2019) Serological Diagnosis of Autoimmune Bullous Skin Diseases. Frontiers in Immunology 10.
Crossref
Crossref
S. Morteza Seyed Jafari, Karolina Gadaldi, Laurence Feldmeyer, Nikhil Yawalkar, Luca Borradori & Christoph Schlapbach. (2019) Effects of Omalizumab on FcεRI and IgE Expression in Lesional Skin of Bullous Pemphigoid. Frontiers in Immunology 10.
Crossref
Crossref
Khalaf Kridin, Christine Ahn, William C. Huang, Ahmed Ansari & Naveed Sami. (2019) Treatment Update of Autoimmune Blistering Diseases. Dermatologic Clinics 37:2, pages 215-228.
Crossref
Crossref
Gudrun F. Debes & Shannon E. McGettigan. (2019) Skin-Associated B Cells in Health and Inflammation. The Journal of Immunology 202:6, pages 1659-1666.
Crossref
Crossref
Cristina Vico‐Alonso, Alba Calleja‐Algarra, Raquel Aragón‐Miguel, Alba Sánchez‐Velázquez, Virginia Velasco‐Tamariz, Pablo Luis Ortiz‐Romero & Verónica Monsálvez‐Honrubia. (2019) Omalizumab as an alternative therapeutic tool in the treatment of bullous pemphigoid: A case report. Dermatologic Therapy 32:2, pages e12829.
Crossref
Crossref
Mareike Witte, Detlef Zillikens & Enno Schmidt. (2018) Diagnosis of Autoimmune Blistering Diseases. Frontiers in Medicine 5.
Crossref
Crossref
K. Kridin. (2018) Peripheral eosinophilia in bullous pemphigoid: prevalence and influence on the clinical manifestation. British Journal of Dermatology 179:5, pages 1141-1147.
Crossref
Crossref
M.M. Holtsche, S. Goletz, N. van Beek, D. Zillikens, S. Benoit, K. HarmanS. WaltonJ. EnglishM. Sticherling, A. ChapmanN.J. LevellR. GrovesH.C. WilliamsI.R. König & E. Schmidt. (2018) Prospective study in bullous pemphigoid: association of high serum anti-BP180 IgG levels with increased mortality and reduced Karnofsky score. British Journal of Dermatology 179:4, pages 918-924.
Crossref
Crossref
Jieyu Zhang, Hui Fang, Shengxian Shen, Erle Dang, Qiuju Li, Pei Qiao, Hongjiang Qiao & Gang Wang. (2018) Identification of Immunodominant Th2-Cell Epitopes in Chinese Patients with Bullous Pemphigoid. Journal of Investigative Dermatology 138:9, pages 1917-1924.
Crossref
Crossref
Kyle T. Amber, Manuel Valdebran, Khalaf Kridin & Sergei A. Grando. (2018) The Role of Eosinophils in Bullous Pemphigoid: A Developing Model of Eosinophil Pathogenicity in Mucocutaneous Disease. Frontiers in Medicine 5.
Crossref
Crossref
K. Eyerich & S. Eyerich. (2018) Immune response patterns in non-communicable inflammatory skin diseases. Journal of the European Academy of Dermatology and Venereology 32:5, pages 692-703.
Crossref
Crossref
Lan Lin, Bin-Jin Hwang, Donna A. Culton, Ning Li, Susan Burette, Beverly H. Koller, Kelly A. Messingham, Janet A. Fairley, James J. Lee, Russell P. Hall, Lijia An, Luis A. Diaz & Zhi Liu. (2018) Eosinophils Mediate Tissue Injury in the Autoimmune Skin Disease Bullous Pemphigoid. Journal of Investigative Dermatology 138:5, pages 1032-1043.
Crossref
Crossref
Hyun Jung Kwon, Ga Ram Ahn, Sun Young Choi, Kapsok Li & Seong Jun Seo. (2018) Explosive bullous pemphigoid with high serum total IgE: Serum IgE as a biomarker that reflects disease activity. JAAD Case Reports 4:4, pages 352-354.
Crossref
Crossref
Marcus Maurer, Sabine Altrichter, Oliver Schmetzer, Jörg Scheffel, Martin K. Church & Martin Metz. (2018) Immunoglobulin E-Mediated Autoimmunity. Frontiers in Immunology 9.
Crossref
Crossref
Michael Kasperkiewicz, Enno Schmidt, Ralf J. Ludwig & Detlef Zillikens. (2018) Targeting IgE Antibodies by Immunoadsorption in Atopic Dermatitis. Frontiers in Immunology 9.
Crossref
Crossref
Frank Antonicelli, Sébastien Le Jan, Julie Plée & Philippe Bernard. 2018. Immunity and Inflammation in Health and Disease. Immunity and Inflammation in Health and Disease
213
222
.
Yale Liu, Liang Li & Yumin Xia. (2017) BP180 Is Critical in the Autoimmunity of Bullous Pemphigoid. Frontiers in Immunology 8.
Crossref
Crossref
Delphine Giusti, Sébastien Le Jan, Gregory Gatouillat, Philippe Bernard, Bach Nga Pham & Frank Antonicelli. (2017) Biomarkers related to bullous pemphigoid activity and outcome. Experimental Dermatology 26:12, pages 1240-1247.
Crossref
Crossref
Minna E. Kubin, Lars Hellberg & Riitta Palatsi. (2017) Glucocorticoids: The mode of action in bullous pemphigoid. Experimental Dermatology 26:12, pages 1253-1260.
Crossref
Crossref
Mor Miodovnik, Axel Künstner, Ewan A. Langan, Detlef Zillikens, Regine Gläser, Eli Sprecher, John F. Baines, Enno Schmidt & Saleh M. Ibrahim. (2017) A distinct cutaneous microbiota profile in autoimmune bullous disease patients. Experimental Dermatology 26:12, pages 1221-1227.
Crossref
Crossref
T. Hashimoto, A. Ohzono, K. Teye, S. Numata, S. Hiroyasu, D. Tsuruta, T. Hachiya, K. Kuroda, M. Hashiguchi, T. Kawakami & N. Ishii. (2017) Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid. British Journal of Dermatology 177:1, pages 141-151.
Crossref
Crossref
Shu Ding, Qiancheng Deng, Yaping Xiang, Jing Chen, Jinhua Huang & Jianyun Lu. (2017) Bullous pemphigoid associated with milia, increased serum IgE, autoantibodies against desmogleins, and refractory treatment in a young patient. Anais Brasileiros de Dermatologia 92:5 suppl 1, pages 34-36.
Crossref
Crossref